Specialty Pharma Journal Specialty, Precision & Technology
London, UK, Carlsbad, CA, April 19, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, today announced that the Peripheral and Central Nervous System Drugs …
Tag Archives: cannabis-based medicine
April, 2018
January, 2018
-
25 January
GW Pharma Announces Publication of Landmark Epidiolex (cannabidiol) Study in The Lancet
London, UK, Carlsbad, CA, January 24, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The Lancet has published results from a Phase 3 …
February, 2017
-
8 February
Cannabics Announces Commercialization of Cannabinoids-Based Personalized Diagnostics for Cancer Patients
BETHESDA, Maryland, Feb. 6, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) today announced it will begin providing personalized cannabinoid anti-tumor tests for cancer patients. The diagnostic tests are based on liquid biopsies of patients suffering from any kind of cancer. The test uses CTC technology that collects cancer cells from patients’ …
-
7 February
GW Pharma’s Cannabis-Derived Drug Shows Promise in Brain Cancer Study
London, UK, 7 Feb 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination …
December, 2016
-
2 December
Cannabics Announces Specific Ratios of Cannabinoids Led to Apoptosis in MD-MB-231 Breast Cancer Cell Viability
BETHESDA, Maryland, Dec. 1, 2016 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that results from the company’s Cancer HTS research indicates that specific ratios of Cannabinoids led to Apoptosis in MDA-MB-231 Breast Cancer cell viability. Cannabics Pharmaceuticals is currently developing a personalized treatment based upon screening of patients’ biopsy …
October, 2016
-
21 October
Cannabics Discovers Specific Ratios of THC/CBD Effectuate Reduction in U87MG Glioblastoma Cell Viability
BETHESDA, Maryland, October 20, 2016 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that results from the company’s latest cancer HTS research overtly conclude that, depending upon the THC/CBD ratio, specific Cannabis extracts are directly contributive to reducing U87MG glioblastoma cell viability. The Company expects that results on additional types …
-
19 October
CNF Presents Cannabis in Epilepsy: A Symposium Designed to Bridge the Gap in Communication
MINNEAPOLIS, Oct. 19, 2016 /PRNewswire-USNewswire/ — The Child Neurology Foundation (CNF) is poised to welcome members of the Child Neurology Society (CNS) interested in seeking a deeper understanding of the current science, family experience and advocacy efforts surrounding the use of cannabis for the treatment of epilepsy. The organization will …
-
7 October
Medical Genomics Partners with Industry Leaders to Develop Genomics-Based Safety and Quality Standards for Medical Cannabis
WOBURN, Mass.–(BUSINESS WIRE)–Medicinal Genomics (MGC), an innovative molecular information company focused on safety, research, and genetics of therapeutic plants, is partnering with a preliminary group of twelve leading cultivators and processors to develop fully-validated, genomics-based safety and quality standards for medical cannabis. The lack of consistency of strains from the …